Abstract
Metformin, a widely used first-line treatment for type 2 diabetes (T2D), is known to reduce blood glucose levels and suppress appetite. Here we report a significant elevation of the appetite-suppressing metabolite N-lactoyl phenylalanine (Lac-Phe) in the blood of individuals treated with metformin across seven observational and interventional studies. Furthermore, Lac-Phe levels were found to rise in response to acute metformin administration and post-prandially in patients with T2D or in metabolically healthy volunteers.
© 2024. The Author(s).
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Appetite / drug effects
-
Appetite Depressants / pharmacology
-
Appetite Depressants / therapeutic use
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 2* / blood
-
Diabetes Mellitus, Type 2* / drug therapy
-
Diabetes Mellitus, Type 2* / metabolism
-
Female
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use
-
Male
-
Metformin* / pharmacology
-
Metformin* / therapeutic use
-
Middle Aged
-
Phenylalanine* / blood
-
Phenylalanine* / metabolism
-
Postprandial Period
Substances
-
Metformin
-
Phenylalanine
-
Hypoglycemic Agents
-
Blood Glucose
-
Appetite Depressants
-
N-lactoyl-phenylalanine